Banque Cantonale Vaudoise’s Beam Therapeutics BEAM Stock Holding History

Banque Cantonale Vaudoise’s Portfolio BEAM Stock Details BEAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$343K	Hold	10,000	–	–	0.05%	135
2026 Q1	$238K	Buy	+10,000	New	+$277K	0.01%	614
2022 Q3	–	Sell	-1,167	Closed	-$45K	–	1234
2022 Q2	$45K	Buy	1,167 +28	+2%	+$1.11K	﹤0.01%	1022
2022 Q1	$65K	Hold	1,139	–	–	﹤0.01%	993
2021 Q4	$91K	Hold	1,139	–	–	﹤0.01%	972
2021 Q3	$99K	Buy	1,139 +139	+14%	+$14K	﹤0.01%	935
2021 Q2	$129K	Hold	1,000	–	–	0.01%	919
2021 Q1	$80K	Hold	1,000	–	–	﹤0.01%	950
2020 Q4	$82K	Hold	1,000	–	–	﹤0.01%	873
2020 Q3	$25K	Buy	+1,000	New	+$24.8K	﹤0.01%	963

Other funds holding BEAM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Banque Cantonale Vaudoise's BEAM Position: Q2 2026 in Review

Banque Cantonale Vaudoise held its Beam Therapeutics (BEAM) position steady in Q2 2026 at 10,000 shares worth $343K. The position accounts for 0.05% of the portfolio, ranked #135.

Banque Cantonale Vaudoise first reported a position in BEAM in Q3 2020 and has held it in 10 quarters since. 278 funds tracked by Wall St. Rank hold BEAM as of Q2 2026.

Banque Cantonale Vaudoise held 10,000 shares of Beam Therapeutics worth $343K as of Q2 2026.
Banque Cantonale Vaudoise left its Beam Therapeutics share count unchanged in Q2 2026.
Beam Therapeutics made up 0.05% of Banque Cantonale Vaudoise's portfolio in Q2 2026, its #135 holding.
Banque Cantonale Vaudoise first reported a position in Beam Therapeutics in Q3 2020 and has held it in 10 quarters since.
278 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2026.

Based on Banque Cantonale Vaudoise's 13F filing for Q2 2026, filed 31 Jul 2026.